Pier Maria Fornasari: Possible New Target for SCD and Beta Thalassemia Treatment
Pier Maria Fornasari, Director of Regenhealthsolutions.info, shared a post on LinkedIn:
“Possible New Target for Sickle Cell Disease and Beta Thalassemia Treatment identified by Harvard Medical School Researchers
BACH2 regulates HbF independently of BCL11A
Researchers identify additional gene controlling production of fetal hemoglobin
Harvard Medical School researchers at Boston Children’s Hospital and Dana-Farber Cancer Institute have identified a new pathway that regulates the production of fetal hemoglobin, a form of hemoglobin that normally gets replaced soon after birth by adult hemoglobin.
Two FDA-approved gene therapies reactivate the production of fetal hemoglobin as a treatment for sickle cell disease and beta thalassemia, which are caused by mutations in adult hemoglobin….”
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 02:46Arman Qamar: Drug-Coated Balloons in Coronary Bifurcation PCI
-
Oct 4, 2026, 01:13Francesc Formiga: Updated Evidence on LAA Closure Versus Oral Anticoagulation in AF
-
Oct 4, 2026, 01:11Alicja Urbaniak: Targeting CD148 to Develop New Antithrombotic Therapies
-
Oct 4, 2026, 01:03Susan Mou: Presenting Long-Term Clinical Outcomes in SCD and TDT
-
Oct 4, 2026, 01:00Mark Johnson: Elevating Patient and Warrior Voices During Sickle Cell Awareness Month
-
Oct 4, 2026, 00:48Sthanu Subramanian: Mechanisms, Clinical Phenotypes, Imaging, and Treatment of CVT
-
Oct 4, 2026, 00:33Ashish Pemawat: Can We Protect the Brain while We Restore Blood Flow?
-
Oct 4, 2026, 00:32Marta Nowakowska-Kotas: Could a Small Rise in Creatinine after Thrombectomy in Stroke Patients Be an Early Warning Sign?
-
Oct 4, 2026, 00:26Mohammad Nafeli Shahrestani: CXCL10 Associated With Increased Long-Term Risk of Ischemic Stroke